Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinovac PCV13 in infants and children
NCT06183216Phase 1Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jan 2024
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sinovac PCV13 in pneumococcal infection (4 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Incidence of adverse reactions. Started Jan 2024; status: completed.
02
Drugs
Sinovac PCV13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06183216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06183216.